Sandra Calvin Sells 3,348 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 3,348 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total value of $67,361.76. Following the transaction, the chief accounting officer now directly owns 63,654 shares in the company, valued at approximately $1,280,718.48. This represents a 5.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sandra Calvin also recently made the following trade(s):

• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total transaction of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00.

Travere Therapeutics Stock Up 3.1 %

Shares of NASDAQ:TVTX opened at $21.86 on Friday. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $22.13. The stock’s 50-day moving average price is $18.80 and its two-hundred day moving average price is $15.56. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds have recently modified their holdings of TVTX. Aigen Investment Management LP acquired a new position in Travere Therapeutics during the third quarter worth approximately $170,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Travere Therapeutics during the 3rd quarter worth $673,000. FMR LLC increased its holdings in shares of Travere Therapeutics by 27.5% during the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock worth $2,062,000 after buying an additional 31,772 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Travere Therapeutics by 30.2% in the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock worth $10,078,000 after buying an additional 167,100 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Travere Therapeutics by 3.9% in the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after acquiring an additional 64,744 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TVTX. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $9.00 to $27.00 in a report on Monday, October 21st. HC Wainwright increased their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. Piper Sandler lifted their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Scotiabank increased their target price on Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald assumed coverage on Travere Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating for the company. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $24.00.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.